NeOnc Technologies Holdings, Inc. Appoints Bader Almonawer to Board of Directors
NeOnc Technologies Holdings (future NASDAQ: NTHI), a clinical-stage medical biotechnology company, has appointed Bader Almonawer to its Board of Directors. Almonawer, currently Managing Partner at Arabian Group, brings over a decade of experience in venture capital, investment banking, and business consulting.
His career includes founding Oasis Capital, a VC fund that invested in successful early-stage startups, and positions at McKinsey & Company, World Bank, Wafra Inc.'s Alternative Investments Division, and Citigroup's M&A advisory division. The appointment aims to leverage his expertise as NeOnc prepares for its public listing and expansion of clinical trials, particularly in the Gulf region.
The company focuses on developing treatments for brain cancer and central nervous system diseases. Almonawer holds degrees from Penn State University, Cornell University, and MIT, where he received various honors including the Halaby Fellowship.
NeOnc Technologies Holdings (futuro NASDAQ: NTHI), una società di biotecnologia medica in fase clinica, ha nominato Bader Almonawer nel suo Consiglio di Amministrazione. Almonawer, attualmente Managing Partner presso Arabian Group, porta con sé oltre un decennio di esperienza in venture capital, investment banking e consulenza aziendale.
La sua carriera include la fondazione di Oasis Capital, un fondo VC che ha investito in startup di successo nella fase iniziale, e posizioni presso McKinsey & Company, Banca Mondiale, Divisione Investimenti Alternativi di Wafra Inc. e divisione di consulenza M&A di Citigroup. La nomina mira a sfruttare la sua esperienza mentre NeOnc si prepara per la sua quotazione pubblica e l'espansione dei trial clinici, in particolare nella regione del Golfo.
La società si concentra sullo sviluppo di trattamenti per il cancro al cervello e le malattie del sistema nervoso centrale. Almonawer ha conseguito lauree presso la Penn State University, la Cornell University e il MIT, dove ha ricevuto vari riconoscimenti, tra cui la Halaby Fellowship.
NeOnc Technologies Holdings (futuro NASDAQ: NTHI), una empresa de biotecnología médica en etapa clínica, ha nombrado a Bader Almonawer en su Junta Directiva. Almonawer, actualmente Managing Partner en Arabian Group, aporta más de una década de experiencia en capital de riesgo, banca de inversión y consultoría empresarial.
Su carrera incluye la fundación de Oasis Capital, un fondo de capital de riesgo que invirtió en startups exitosas en etapas tempranas, y puestos en McKinsey & Company, el Banco Mundial, la División de Inversiones Alternativas de Wafra Inc. y la división de asesoría M&A de Citigroup. La designación tiene como objetivo aprovechar su experiencia mientras NeOnc se prepara para su salida a bolsa y la expansión de ensayos clínicos, particularmente en la región del Golfo.
La empresa se centra en desarrollar tratamientos para el cáncer cerebral y enfermedades del sistema nervioso central. Almonawer tiene títulos de la Penn State University, Cornell University y MIT, donde recibió varios honores, incluida la Halaby Fellowship.
NeOnc Technologies Holdings (미래 NASDAQ: NTHI)는 임상 단계의 의료 생명공학 회사로, Bader Almonawer를 이사회의 일원으로 임명했습니다. Almonawer는 현재 Arabian Group의 매니징 파트너로서 벤처 캐피탈, 투자 은행 및 비즈니스 컨설팅 분야에서 10년 이상의 경험을 가지고 있습니다.
그의 경력에는 성공적인 초기 단계 스타트업에 투자한 VC 펀드인 Oasis Capital의 설립과 McKinsey & Company, 세계은행, Wafra Inc.의 대체 투자 부서 및 Citigroup의 M&A 자문 부서에서의 경력이 포함됩니다. 이번 임명은 NeOnc가 상장 준비와 임상 시험 확장을 준비하는 과정에서 그의 전문성을 활용하기 위한 것입니다. 특히 걸프 지역에서의 확장을 목표로 하고 있습니다.
회사는 뇌암 및 중추신경계 질환 치료제를 개발하는 데 중점을 두고 있습니다. Almonawer는 Penn State University, Cornell University 및 MIT에서 학위를 취득했으며, Halaby Fellowship을 포함한 여러 상을 수상했습니다.
NeOnc Technologies Holdings (futur NASDAQ: NTHI), une entreprise de biotechnologie médicale en phase clinique, a nommé Bader Almonawer au sein de son Conseil d'Administration. Almonawer, actuellement Managing Partner chez Arabian Group, apporte plus d'une décennie d'expérience en capital-risque, banque d'investissement et conseil aux entreprises.
Sa carrière comprend la fondation d'Oasis Capital, un fonds de capital-risque ayant investi dans des startups réussies en phase initiale, ainsi que des postes chez McKinsey & Company, la Banque mondiale, la Division des investissements alternatifs de Wafra Inc. et la division de conseil en fusions et acquisitions de Citigroup. Cette nomination vise à tirer parti de son expertise alors que NeOnc se prépare à son introduction en bourse et à l'expansion des essais cliniques, notamment dans la région du Golfe.
L'entreprise se concentre sur le développement de traitements pour le cancer du cerveau et les maladies du système nerveux central. Almonawer détient des diplômes de la Penn State University, de la Cornell University et du MIT, où il a reçu plusieurs distinctions, dont la Halaby Fellowship.
NeOnc Technologies Holdings (zukünftige NASDAQ: NTHI), ein biomedizinisches Unternehmen in der klinischen Phase, hat Bader Almonawer in seinen Vorstand berufen. Almonawer, der derzeit Managing Partner bei Arabian Group ist, bringt über ein Jahrzehnt Erfahrung in den Bereichen Risikokapital, Investment Banking und Unternehmensberatung mit.
Seine Karriere umfasst die Gründung von Oasis Capital, einem VC-Fonds, der in erfolgreiche Startups in der Frühphase investierte, sowie Positionen bei McKinsey & Company, der Weltbank, der Abteilung für alternative Investitionen von Wafra Inc. und der M&A-Beratung von Citigroup. Die Ernennung zielt darauf ab, seine Expertise zu nutzen, während NeOnc sich auf den Börsengang und die Expansion klinischer Studien, insbesondere in der Golfregion, vorbereitet.
Das Unternehmen konzentriert sich auf die Entwicklung von Behandlungen für Gehirnkrebserkrankungen und Erkrankungen des zentralen Nervensystems. Almonawer hat Abschlüsse von der Penn State University, der Cornell University und dem MIT, wo er verschiedene Auszeichnungen erhielt, darunter das Halaby Fellowship.
- Strategic board appointment brings M&A and capital markets expertise ahead of NASDAQ listing
- New director's Gulf region connections could facilitate expansion of clinical trials
- Addition of venture capital expertise could help with future funding opportunities
- Company is still in clinical-stage with no marketed products
- Upcoming NASDAQ listing suggests potential dilution for existing shareholders
Almonawer adds broad financial expertise to the NeOnc team
WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (to be listed on the NASDAQ Global Market under the symbol: NTHI), a clinical-stage medical biotechnology company, announced today that it has appointed Bader Almonawer, Managing Partner at Arabian Group, a provider of insurance solutions, to its Board of Directors. Almonawer brings significant financial and business expertise to NeOnc.
"Bader brings a wealth of capital markets and M&A experience to NeOnc,” said Dr. Thomas Chen, Chief Executive Officer of NeOnc. “His extensive finance background will serve us well as we embark on our public company journey and work toward providing enduring value to all of our stakeholders.”
Almonawer is a seasoned professional with more than a decade of experience in venture capital, investment banking, and business consulting and development. Beginning his career in 2016 with McKinsey & Company and the World Bank, he later founded Oasis Capital, a VC fund that invested in numerous early-stage startups, many of which have flourished into multibillion-dollar corporations. Later, he joined Wafra Inc.'s Alternative Investments Division and gained further M&A experience at Citigroup’s M&A advisory division.
“NeOnc is focused on bringing innovative medicines to diseases with high unmet needs, and I look forward to providing counsel that will help the Company achieve this goal,” said Almonawer. “With the ever-shifting dynamics of the biotech landscape, the importance of transformative treatments, such as the ones NeOnc is developing, is paramount.”
“Bader’s expertise in global finance, private equity, and venture capital will be a significant asset to NeOnc as we navigate the next stage of our growth,” said Amir Heshmatpour, NeOnc’s Executive Chairman. “His strategic insights will play a crucial role in advancing our mission to bring life-changing treatments to patients battling brain cancer and other central nervous system diseases. As we expand our trials beyond the U.S., hopefully soon into the Gulf region, we believe that Bader’s regional knowledge and global perspective will be instrumental in our efforts to forge key partnerships and ensuring our therapies reach those who need them most.”
Almonawer earned his Bachelor of Science in Industrial Engineering and Operations Research from Penn State University before obtaining a Master of Arts in Economics and Financial Policy from Cornell University, where he received Pi Alpha honors. He completed his Master of Business Administration at the Massachusetts Institute of Technology (MIT), earning the Halaby Fellowship, a merit-based fellowship recognizing his exceptional academic excellence and professional achievements.
ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.
For more about NeOnc and its pioneering technology, visit neonctech.com.
Important Cautions Regarding Forward Looking Statements
All statements other than statements of historical facts included in this press release are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Generally, such forward-looking statements include statements regarding expectations, possible or assumed future actions, business strategies, events or results of operations, including statements regarding expectations or predictions or future financial or business performance or conditions and those statements that use forward-looking words such as "projected," "expect," "possibility" and "anticipate," or similar expressions. The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties, and assumptions. Actual results could differ materially from current projections or implied results. The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management are under no obligation, and expressly disclaim any obligation, to update, alter or otherwise revise any forward-looking statements following the date of this news release, whether because of new information, future events or otherwise, except as required by law.
“NEO100” is a registered trademark of NeOnc Technologies Holdings, Inc.
Company Contact:
Patrick Walters
Chief Operations Officer
NeOnc Technologies Holdings, Inc.
info@neonc.com
Investor Relations:
Roger Pondel / Laurie Berman
PondelWilkinson Inc.
(310) 279-5980
rpondel@pondel.com
lberman@pondel.com
FAQ
What is the significance of Bader Almonawer joining NTHI's Board of Directors?
What are NeOnc Technologies' (NTHI) main business focus areas?
When is NTHI expected to be listed on NASDAQ?
What is Bader Almonawer's professional background before joining NTHI?
